Why Do Biologics Trigger TB Testing Requirements?
Certain biologics, particularly tumor necrosis factor (TNF) inhibitors like infliximab (Remicade), adalimumab (Humira), and etanercept (Enbrel), require tuberculosis (TB) testing before starting treatment. These drugs suppress parts of the immune system that fight infections, including latent TB—a dormant form of the bacterium Mycobacterium tuberculosis that infects about one-quarter of the world's population without causing active disease.[1]
How TNF Blockers Increase TB Risk
TNF-alpha is a cytokine essential for forming granulomas, which wall off latent TB bacteria in the lungs and prevent reactivation. Blocking TNF with these biologics disrupts this barrier, allowing dormant TB to reactivate into active, contagious disease. Clinical data show patients on TNF inhibitors face 2- to 20-fold higher TB risk compared to the general population, with most cases linked to latent infections reactivated shortly after starting therapy.[2][3]
The FDA mandates screening via interferon-gamma release assays (IGRA, like QuantiFERON-TB Gold) or tuberculin skin tests (TST) before initiating these drugs. Positive results prompt treatment for latent TB (typically 3-9 months of isoniazid or rifampin-based regimens) before or alongside the biologic.[4]
Which Biologics Specifically Require It?
Primarily TNF-alpha inhibitors used for autoimmune conditions like rheumatoid arthritis, Crohn's disease, psoriasis, and ankylosing spondylitis:
- Infliximab, adalimumab, certolizumab, golimumab, etanercept.
Other immunosuppressants like IL-17 inhibitors (secukinumab, ixekizumab) or IL-12/23 blockers (ustekinumab) carry lower but notable TB risks, often requiring similar screening per product labels or guidelines from the American College of Rheumatology.[5]
Non-TNF biologics like rituximab or most monoclonal antibodies for cancer (e.g., rituximab) rarely mandate routine TB testing unless patients have TB risk factors.
| Biologic Class | Key Examples | TB Screening Routine? | Risk Level |
|---------------|--------------|-----------------------|------------|
| TNF inhibitors | Humira, Remicade, Enbrel | Yes, required | High |
| IL-17 inhibitors | Cosentyx, Taltz | Often recommended | Moderate |
| IL-12/23 inhibitors | Stelara | Case-by-case | Low-moderate |
| Others (e.g., B-cell depleters) | Rituxan | Rarely | Low |
What Happens During TB Screening and Follow-Up?
- Pre-treatment test: IGRA preferred over TST as it's more specific and unaffected by prior BCG vaccination.
- Positive latent TB: Delay biologic until 1-3 months into anti-TB prophylaxis; monitor closely.
- Active TB: Treat fully before starting biologic.
- Re-testing: Annual checks during long-term therapy, especially in high-prevalence areas or with risk factors like recent travel to TB-endemic regions (e.g., India, sub-Saharan Africa).[6]
Failure to screen has led to outbreaks; a 2001 infliximab trial reported five TB cases among 500 patients, prompting black-box warnings.[7]
TB Risks in High-Prevalence Regions or Special Populations
Patients from or traveling to TB-hotspots face amplified risks—up to 145 cases per 100,000 patient-years on anti-TNF therapy in some studies. Elderly patients, those with diabetes, or on corticosteroids alongside biologics see even higher odds. Biosimilars of TNF inhibitors (e.g., adalimumab biosimilars like Amjevita) carry identical requirements.[8]
Exceptions and When Testing Might Be Skipped
No screening for biologics without TNF involvement or in ultra-low-risk patients (e.g., young, BCG-unvaccinated from low-prevalence countries with negative history). Guidelines evolve; IGRA-only approaches reduce false positives in vaccinated populations.[9]
Sources
[1]: WHO TB Factsheet
[2]: NEJM: TNF Inhibition and TB
[3]: CDC: TB Risk with Biologics
[4]: FDA Remicade Label
[5]: ACR Guidelines
[6]: EULAR Recommendations
[7]: FDA Advisory
[8]: Lancet Infect Dis Review
[9]: ATS/IDSA Statement